1953. Immune responses, viral shedding, and COVID-19 symptom burden from breakthrough SARS-CoV-2 infection in a 2:1 randomized, double-blind, placebo-controlled Phase 3 study of AZD1222 (ChAdOx1 nCoV-19) vaccination
Department
Infectious Diseases
Document Type
Conference Proceeding
Publication Title
Open Forum Infectious Diseases
Conference Name
IDWeek
Conference Date
2022-10-19 - 2022-10-23
First Page
ofac492.1579
DOI
10.1093/ofid/ofac492.1579
Volume
9
Issue
Supplement_2
Publication Date
12-1-2022
Recommended Citation
Sobieszczyk, M. E., & Falsey, A. R. (2022). 1953. Immune responses, viral shedding, and COVID-19 symptom burden from breakthrough SARS-CoV-2 infection in a 2:1 randomized, double-blind, placebo-controlled Phase 3 study of AZD1222 (ChAdOx1 nCoV-19) vaccination. Open Forum Infectious Diseases, 9 (Supplement_2), ofac492.1579. https://doi.org/10.1093/ofid/ofac492.1579
COinS
Comments
See full list of authors at journal website.
Session: 226. COVID-19: Vaccines